Results 221 to 230 of about 553,015 (386)

Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

The Efficacy of Aromatherapy on Pain and Anxiety During Needle-Related Procedures in Adults: A Systematic Review and Meta-Analysis [Letter]. [PDF]

J Pain Res
Wang Z, Ke S, Liu Q.
europepmc   +1 more source

Are open-Label Placebos Ethical? Informed Consent and Ethical Equivocations.

Bioethics, 2016
Charlotte Blease, L. Colloca, Ted J. Kaptchuk   +2 more
semanticscholar   +1 more source

Sobre placebo e efeito placebo [PDF]

Revista Latinoamericana de Psicopatologia Fundamental, 2002
Erney Plessmann de Camargo, Mônica Teixeira   +1 more
openaire   +2 more sources

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

Transitioning from deceptive to nondeceptive placebo treatment to reduce pathological skin-picking. [PDF]

Discov Ment Health
Schienle A, Wilhelm J, Tanzmeister S.
europepmc   +1 more source

Placebo Reactor [PDF]

Nature, 1963
openaire   +2 more sources

Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database

Arthritis &Rheumatology, Accepted Article.
Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source

Would You Take an Open-Label Placebo Pill or Give One to Your Child? Findings from a Cross-Sectional Survey

Psychology Research and Behavior Management
Anne Schienle, Arved Seibel Department of Clinical Psychology, University of Graz, Graz, AustriaCorrespondence: Anne Schienle, Email anne.schienle@uni-graz.atBackground: Open-label placebos (OLPs), honestly prescribed regarding their inert nature, have ...
Schienle A, Seibel A
doaj  

Has the time come to stop using control groups in trials of psychosocial interventions? [PDF]

World Psychiatry
Cuijpers P.
europepmc   +1 more source